Scientific Sessions 2024  /  The Future of Lipid Management: Using Lessons From Our Past  /  The Discovery of the LDL-Receptor and It's Potential as a Target
Logo

American Heart Association

  114
  0

Final ID:

The Discovery of the LDL-Receptor and It's Potential as a Target

  • Goldstein, Joseph  ( UTSW MEDICAL CTR , Dallas , Texas , United States )
  • Brown, Michael  ( UT SOUTHWESTERN MED CTR , Dallas , Texas , United States )
  • Ballantyne, Christie  ( BAYLOR COLLEGE MEDICINE , Houston , Texas , United States )
    • Author Disclosures:
    Joseph Goldstein: No Answer | Michael Brown: No Answer | Christie Ballantyne: DO have relevant financial relationships ; Independent Contractor:Abbott Diagnostic, Akcea, Amgen, Arrowhead, Ionis, Lilly, Merck, New Amsterdam, Novartis, Novo Nordisk:Active (exists now) ; Consultant:Abbott Diagnostic, Amgen, Arrowhead, Astra Zeneca, Denka Seiken, Eli Lilly, Esperion, Illumina, Ionis, Merck, New Amsterdam, Novartis, Novo Nordisk, Roche Diagnostic, TenSixteen Bio:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

The Future of Lipid Management: Using Lessons From Our Past

Saturday, 11/16/2024 , 01:30PM - 02:45PM

Cardiovascular Seminar

More abstracts on this topic:
Gene Therapy and the Potential LDL-Cholesterol "Cure"

Parikh Victoria, Knowles Josh, Khera Amit, Kathiresan Sekar

The Evolution from Statins to Monoclonal Antibodies and Antisense Technology for Lipid Lowering

Michos Erin, Crooke Rosanne, Shapiro Michael

More abstracts from these authors:
Targets, Tools, and Tailored Therapy: What's New and What's Next in Lipid Management for Coronary Atherosclerosis

Ballantyne Christie

The Next Era in Cardiometabolic Treatment

Ballantyne Christie

You have to be authorized to contact abstract author. Please, Login
Not Available